Back to top
more

bluebird bio (BLUE)

(Real Time Quote from BATS)

$0.96 USD

0.96
492,676

-0.01 (-1.09%)

Updated Apr 24, 2024 10:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

by Zacks Equity Research

bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.

bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates

by Zacks Equity Research

bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.

Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up

by Zacks Equity Research

bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.

Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.46% and 5.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -450% and 4.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

by Zacks Equity Research

Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.

Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.

Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia

by Zacks Equity Research

This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

by Zacks Equity Research

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

Why bluebird (BLUE) Stock Might be a Great Pick

by Zacks Equity Research

bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More

by Zacks Equity Research

Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.

bluebird (BLUE) Stock Down on Raising Additional Capital

by Zacks Equity Research

bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

by Zacks Equity Research

Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

by Zacks Equity Research

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News

by Zacks Equity Research

bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

by Zacks Equity Research

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

Ekta Bagri headshot

3 Biotechs With Promising Gene Therapies in the Spotlight

by Ekta Bagri

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies

by Zacks Equity Research

The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.

bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD

by Zacks Equity Research

bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.

CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy

by Zacks Equity Research

CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.

Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How

by Zacks Equity Research

bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.